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Abstract
Background: A high number of elderly people with multiple comorbidities are exposed to the risk of
polypharmacy and prescription of potentially inappropriate medication (PIM). The purpose of this study was to
determine the prevalence and patterns of PIM prescription in Korean older adults according to the 2012 Beers
Criteria.
Methods: A retrospective study was conducted using data from the Korean Health Insurance Review and
Assessment (KHIRA) database of outpatient prescription claims collected from January 1, 2009 to December 31,
2011. A total of 523,811 elderly subjects aged 65 years and older were included in the study, and several covariates
related to the prescription of PIMs were obtained from the KHIRA database. These covariates were analyzed using
Student’s t test and the chi-square test; furthermore, multivariate logistic regression analysis was used to evaluate
the risk factors associated with the prescription of PIMs.
Results: A total of 80.96 % subjects were prescribed at least one PIM independent of their diagnosis or condition
according to the 2012 Beers Criteria. The most commonly prescribed medication class was first-generation
antihistamines with anticholinergic properties (52.33 %). Pain medications (43.04 %) and benzodiazepines (42.53 %)
were next in line. When considering subjects’ diagnoses or conditions, subjects diagnosed with central nervous
system conditions were most often prescribed PIMs. Female sex, severity of comorbidities, and polypharmacy were
significant risk factors for PIM prescriptions.
Conclusions: This study confirmed that PIM prescription is common among elderly Koreans. A clinical decision
support system should be developed to decrease the prevalence of PIM prescriptions.
Keywords: Potentially inappropriate medication (PIM), Beers Criteria, Polypharmacy, Adverse drug effects (ADEs)
Background
As of 2011, elderly adults over 65 years old make up
around 11.3 % of the Korean population. This is ex-
pected to continue to increase to 14 % by 2018, which
would make the Korean population an “aged society” [1, 2].
Elderly adults are more likely to have more than one
chronic illness or condition, which would require the
concomitant prescription of several drugs. This makes
them more vulnerable to the prescription of poten-
tially inappropriate medications (PIMs), which can lead
to an increased risk of adverse drug effects and unneces-
sary hospitalizations [3].
PIMs in older adults can be categorized into three
groups: inappropriate medications regardless of comor-
bidities, medications that may exacerbate underlying dis-
eases, and medications that may interact with other
medications already in use [4]. Guidelines for PIMs have
been developed in many countries, including the United
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States [5], Canada [4], France [6], Ireland [7], Australia
[8], Norway [9], and South Korea [10]. Among these
guidelines, the Beers Criteria, which were developed to
be used as a guideline to avoid inappropriate prescribing
in older adults, are the most commonly used explicit cri-
teria for retrospective studies on the prescription rate of
PIMs [11].
The Beers Criteria were initially developed and pub-
lished by Beers and colleagues for nursing home resi-
dents in 1991 [12], and were subsequently expanded and
revised in 1997 [13] and 2003 [14] to include all geriatric
care settings. Then, an updated version was published in
2012 and was supported by the American Geriatrics
Society. As a result, the 2012 Beers Criteria comprise
fifty-three medications and medication classes divided
into three categories: PIMs and classes to avoid in all
older adults, PIMs and classes to avoid in older adults
with certain diseases and syndromes that the drugs listed
may exacerbate, and medications to be used with cau-
tion in older adults [5].
Researchers suggest that the PIMs specified in the Beers
Criteria can exacerbate the condition and prognosis of
older adults and have a negative influence on healthcare
outcomes [3, 15–17]. In the case of the Korean popula-
tion, clinicians have reported on the prevalence of PIMs in
community-dwelling elderly [18], in older outpatients just
before their admission to a general hospital [19], in a mix-
ture of outpatients and inpatients in a general hospital
[20], and in long-term care facilities [21]. However, no
study has yet systematically examined PIM prescription
rates in a population sample large enough to be represen-
tative of the entire Korean population.
The aim of this study was to determine the prevalence
and patterns of PIM prescription in Korean older adults
according to the 2012 Beers Criteria.
Methods
Data source
The study population was an assembly of three annual
samples drawn from the Korean Health Insurance Review
and Assessment (KHIRA) service database. It contains
medical claims data for the entire Korean population as a
result of the National Health Insurance System [22]. Each
annual sample was randomly taken from 32 strata that
were divided according to gender and age groups. Age
groups were divided into sixteen 5-year age groups and
subjects aged over 65 years were selected for this study.
The sample size was 3 % of the entire Korean population.
The present study was submitted to the institutional
review board of Seoul National University Bundang Hos-
pital (reference number X-1307/209-904), and exempted
from review because the data utilized for analysis was
completely de-identified.
Study population and medications
Subjects aged over 65 years at the time of a prescription,
filling one or more prescription claim in 2009, 2010, or
2011 were included in the study. We excluded inpatients,
and instead focused on outpatient prescriptions. The com-
bined database for the three years contained information
on 523,811 elderly subjects and a total of 45,727,527 pre-
scriptions, from January 1, 2009, to December 31, 2011.
When these prescriptions were examined separately by
year, 19,165,885 prescriptions were from 2009; 13,201,065
were from 2010; and 13,360,577 were from 2011. Prescrip-
tion information included the generic and trade names,
prescription date, duration, and route of administration.
PIM prescription was assessed using the 2012 Beers Cri-
teria [5]. We used two lists: one of individual medications
or medication classes that are inappropriate for any
patient aged 65 years and older, and the other of medica-
tions or medication classes that should be avoided for
patients with certain diseases or syndromes. The list for
medications to be used with caution in older adults was
not included in the analysis because the data was based on
claims data and the actual condition of the patients could
not been assessed. In this study, we determined the preva-
lence of PIM prescriptions for these lists separately. All
medications that were not available in Korea were ex-
cluded from the analysis.
Covariates
Data concerning subjects’ age, gender, number of medi-
cations prescribed, types of healthcare facilities (long-
term care, primary care, secondary care [which typically
refers to large community but non-teaching hospitals],
or tertiary care [which usually refers to a teaching or
university hospital]) [22], residential area (urban or
rural), type of insurance (national health insurance, med-
ical aid, or veteran’s relief ), and the number of out-
patient department visits within one year were obtained
from the database. Subjects were categorized by their
age (65–69, 70–74, 75–79, 80–84, and ≥85), and the
medical specialties that the subjects visited were classi-
fied into three groups: physicians, surgeons, and others.
The specifics of each medical specialty subgroup are
listed in Table 1. Subjects that had been prescribed at
least one PIM, were divided into two subgroups. The
first subgroup included subjects prescribed 1–4 PIMs,
and the second subgroup included subjects prescribed
≥5 PIMs.
Diagnoses were coded according to the International
Statistical Classification of Diseases and Related Health
Problems, 10th revision (ICD-10) [23]. Codes for the fol-
lowing comorbidities were collected (see Additional file 1:
Table S1): hypertension, diabetes mellitus, hyperlipidemia,
cardiovascular disease, heart failure, dementia and cognitive
impairment, transient ischemic attack or ischemic stroke,
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65–69 85,169 (40.16) 101,098 (32.43) 186,267 (35.56)
70–74 62,964 (29.69) 85,631 (27.47) 148,595 (28.37)
75–79 37,059 (17.47) 62,664 (20.10) 99,723 (19.04)
80–84 17,559 (8.28) 38,087 (12.22) 55,646 (10.62)
≥85 9,331 (4.40) 24,249 (7.78) 33,580 (6.41)
No. of medications prescribed
0–5 83,104 (39.18) 99,179 (31.82) 182,283 (34.80)
6–9 106,319 (50.13) 169,554 (54.39) 275,873 (52.67)
≥10 22,659 (10.68) 42,996 (13.79) 65,655 (12.53)
No. of medications from Beers Criteria 2012
0 45,721 (21.56) 54,026 (17.33) 99,747 (19.04)
1–4 155,456 (73.30) 237,099 (76.06) 392,555 (74.94)
≥5 10,905 (5.14) 20,604 (6.61) 31,509 (6.02)
Visited specialtya
Physicianb 99,893 (54.14) 138,452 (51.48) 238,345 (52.56)
Surgeonc 56,601 (30.68) 72,949 (27.12) 129,550 (28.57)
Othersd 28,014 (15.18) 57,548 (21.40) 85,562 (18.87)
Types of healthcare facilitiesa
Long-term care 2,928 (1.58) 6,518 (2.41) 9,446 (2.08)
Primary care 129,480 (69.98) 200,631 (74.33) 330,111 (72.56)
Secondary care 13,695 (7.40) 20,414 (7.56) 34,109 (7.50)
Tertiary care 38,923 (21.04) 42,342 (15.69) 81,265 (17.86)
Residential areaa
Urban 94,571 (44.60) 131,528 (42.21) 226,099 (43.17)
Rural 117,488 (55.40) 180,104 (57.79) 297,628 (56.83)
Type of insurance
National Health Insurance 197,538 (93.14) 276,179 (88.60) 473,717 (90.44)
Medical Aid, Veteran’s Relief 14,544 (6.86) 35,550 (11.40) 50,094 (9.56)
No. of OPDe visits within one year
0 or 1 191,787 (90.43) 285,795 (91.68) 477,582 (91.17)
2–4 12,254 (5.78) 14,580 (4.68) 26,834 (5.12)
≥5 8,041 (3.79) 11,354 (3.64) 19,395 (3.70)
Comorbidities
Hypertension 126,438 (59.62) 209,452 (67.19) 335,890 (64.12)
Diabetes mellitus 71,857 (33.88) 104,600 (33.55) 176,457 (33.69)
Hyperlipidemia 71,736 (33.82) 123,920 (39.75) 195,656 (37.35)
Cardiovascular disease (MIf or angina) 31,599 (14.90) 42,366 (13.59) 73,965 (14.12)
Heart failure 22,570 (10.64) 43,549 (13.97) 66,119 (12.62)
Dementia and cognitive impairment 17,334 (8.17) 36,658 (11.76) 53,992 (10.31)
Cerebrovascular disease (TIAg) 45,832 (21.61) 69,881 (22.42) 115,713 (22.09)
Peripheral artery disease (PADi) 38,829 (18.31) 65,826 (21.12) 104,655 (19.98)
Chronic kidney disease 6,664 (3.14) 5,847 (1.88) 12,511 (2.39)
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peripheral artery disease, chronic kidney disease, liver cir-
rhosis, chronic lung disease, systemic cancer, and depres-
sion. The Charlson Comorbidity Index [24] was used to
estimate the severity of comorbidities of the study popula-
tion. Polypharmacy was defined as concurrent use of six or
more drugs, in accordance with a study in which the poten-
tial for inappropriate prescribing has been shown to
increase greatly at this threshold [25]. Potential interactions
with age, gender, and the Charlson Comorbidity Index (for
the number of comorbidities) were explored and none were
observed.
Statistical analysis
Statistical analyses were performed using the SAS soft-
ware, version 9.3 (Cary, North Carolina). We evaluated
subjects’ baseline characteristics using the Student’s t test
for continuous variables and the χ2 test for categorical var-
iables. Multivariate logistic regression analysis was used to
evaluate risk factors associated with the prescription of
PIMs.
Results
The baseline characteristics of the study population are
shown in Table 1. Subjects’ mean age was 73.32 ±
14.44 years, and 59.51 % of subjects were women. Of the
523,811 subjects, a total of 424,064 (80.96 %) were pre-
scribed at least one PIM independent of diagnoses or con-
ditions according to the 2012 Beers Criteria. Most
subjects were prescribed one (26.86 %) or two (23.86 %)
PIMs; however, the prevalences of three (15.78 %) or four
(8.44 %) PIM prescriptions were also high. Table 1 also in-
cludes the total number of medications prescribed and the
number of medications prescribed from the Beers Criteria.
The medications that were not included in the analysis are
shown separately (see Additional file 2: Table S2).
Table 2 shows the prevalence of PIM classes that are
independent of diagnosis or condition, whereas Table 3
shows the prevalence of PIM classes in specific diagno-
ses or conditions. The most commonly prescribed medi-
cation class independent of diagnosis or condition was
first-generation antihistamines with anticholinergic
properties (52.33 %). Pain medications (43.04 %) and
benzodiazepines (short, intermediate, and long acting;
42.53 %) were next in line. Among the PIM prescriptions
considering diagnoses or conditions, subjects diagnosed
with delirium (82.21 %), dementia and cognitive impair-
ment (80.24 %) were the most likely to be prescribed
PIMs. Elderly patients with heart failure, gastrointestinal
disorders, and chronic kidney conditions were also often
prescribed PIMs (Table 3).
The results of the multivariate regression analysis to
identify the factors associated with prescription of PIMs,
independent of disease or condition, are presented in
Table 4. Female sex (OR = 1.19 and 1.53, respectively),
specialties other than physician (that is, surgeon or
other; OR = 1.23 and 1.46), severity of comorbidities
(OR = 1.21 and 2.25), and polypharmacy (OR = 3.51 and
7.81) were associated factors with PIM prescribing in
both subjects with 1–4 PIM and subjects with ≥5 PIM
claims. On the other hand, younger age; secondary, ter-
tiary, or long-term healthcare facilities (OR = 0.84 and
0.72); being insured by national health insurance (OR =
0.88 and 0.83); and having not more than one outpatient
department visit within the same year (OR = 0.79 and
0.68) showed a decreased association with PIM prescrip-
tion. Residing in a rural area was positively associated
with an increased PIM prescription in subjects with 1–4
PIM claims, whereas in subjects with ≥5 PIM claims, it
was negatively associated.
Charlson Comorbidity Index score and total number of
medications were positively correlated with each other
(Pearson correlation coefficient = 0.29; p < 0.0001). The
results of a stratified logistic regression analysis for sever-
ity of disease and total number of medications showed
Table 1 Baseline characteristics (N = 523,811) (Continued)
Liver cirrhosis 51,766 (24.41) 67,601 (21.69) 119,367 (22.79)
Chronic lung disease (asthma, COPDh) 75,575 (35.63) 105,636 (33.89) 181,211 (34.59)
Cancer 39,935 (18.83) 38,203 (12.26) 78,138 (14.92)
Depression 19,635 (9.26) 42,375 (13.59) 62,010 (11.84)
Charlson Comorbidity Index
0–1 83,991 (39.60) 122,379 (39.26) 206,370 (39.40)
2–4 81,114 (38.25) 129,131 (41.42) 210,245 (40.14)
≥5 46,977 (22.15) 60,219 (19.32) 107,196 (20.46)
aMissing data were excluded. Percentages (%) were calculated after excluding the missing data; bIncludes: emergency medicine, family medicine, general
medicine, internal medicine, neurology, occupational & environmental medicine, pediatrics, psychiatry, rehabilitation medicine, and tuberculosis department;
cIncludes: cardiothoracic surgery, dermatology, general surgery, neurosurgery, orthopedics, otorhinolaryngology, and urology; dIncludes: anesthesiology, dentistry,
laboratory medicine, nuclear medicine, oriental medicine, pathology, preventive medicine, radiology, and radiation oncology; eOPD outpatient department; fMI,
myocardial infarction; gTIA, transient ischemic attack; hCOPD, chronic obstructive pulmonary disease; iPAD, peripheral artery disease
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Anticholinergics (excludes TCAsa) First-generation antihistamines 105,474 (49.73) 168,642 (54.10) 274,116 (52.33)
Cardiovascularb 34,748 (16.38) 13,499 (4.33) 48,247 (9.21)
Central nervous system 102,334 (48.25) 209,620 (67.24) 311,954 (59.55)
Antipsychotics 2,979 (1.40) 4,943 (1.59) 7,922 (1.51)
Tertiary TCAsc 11,876 (5.60) 23,220 (7.45) 35,096 (6.70)
Barbiturates 1,043 (0.49) 1,811 (0.58) 2,854 (0.54)
Benzodiazepines 71,452 (33.69) 151,334 (48.55) 222,786 (42.53)
Nonbenzodiazepine hypnotics 14,984 (7.07) 28,312 (9.08) 43,296 (8.27)
Endocrine 6,100 (2.88) 9,128 (2.93) 15,228 (2.91)
Gastrointestinal 18,028 (8.50) 35,961 (11.54) 53,989 (10.31)
Pain 82,101 (38.71) 143,334 (45.98) 225,435 (43.04)
Skeletal muscle relaxants 18,495 (8.72) 36,266 (11.63) 54,761 (10.45)
aTCAs, tricyclic antidepressants; bIncludes: alpha-agonist (reserpine >0.1 mg/d), alpha-blocker, antiarrhythmic drugs, and digoxin (>0.125 mg/d); cIncludes: doxepin
>6 mg/d
Table 3 Prevalence of prescriptions of potentially inappropriate medications for specific diagnoses or conditions for elderly patients
(N = 523,811)a










Heart failure (n = 66,119) 11,624 (17.58) 25,003 (37.82) 36,627 (55.40)
Syncope (n = 4,871) 573 (11.76) 509 (10.45) 1,082 (22.21)
Central nervous system
Chronic seizures or epilepsy (n = 16,940) 2,357 (13.91) 3,502 (20.67) 5,859 (34.59)
Delirium (n = 3,906) 1,410 (36.10) 1,801 (46.11) 3,211 (82.21)
Dementia and cognitive impairment (n = 53,992) 13,557 (25.11) 29,767 (55.13) 43,324 (80.24)
History of falls or fractures (n = 76,721) 10,844 (14.13) 34,504 (44.97) 45,348 (59.11)
Insomnia (n = 68,919) 7,668 (11.13) 13,876 (20.13) 21,544 (31.26)
Parkinson's disease (n = 13,662) 557 (4.08) 1,277 (9.35) 1,834 (13.42)
Gastrointestinal
Chronic constipation (n = 112,212) 26,920 (23.99) 44,320 (39.50) 71,240 (63.49)
History of gastric or duodenal ulcers (n = 173,326) 30,178 (17.41) 58,069 (33.50) 88,247 (50.91)
Kidney and urinary tract
Chronic kidney disease Stages IV and V (n = 12,511) 4,153 (33.19) 3,650 (29.17) 7,803 (62.37)
LUTS/BPHc in men (n = 68,096) 37,826 (55.55) - 37,826 (55.55)
Urinary incontinence (all types) in women (n = 28,368) - 118 (0.42) 118 (0.42)
Stress or mixed urinary incontinence (n = 6,759) - 369 (5.46) 369 (5.46)
aThe prevalences were significantly different between male and female for each diagnosis or condition (P<0.0001); bPercentages (%) with respect to male, female,
and total populations for each diagnosis or condition, respectively; cLUTS/BPH, lower urinary tract symptoms/benign prostatic hyperplasia
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that individuals are more likely to have more PIMs if they
take a greater number of total medications (see Additional
file 3: Table S3).
Discussion
The results of this population-based study confirmed
that PIM prescription is common among elderly Korean
subjects: namely, PIM prescriptions independent of diag-
nosis or condition were found in 80.96 % of prescriptions,
while as many as 82.21 % had PIM prescriptions consider-
ing specific diagnoses or conditions. This is a much higher
rate than those reported in previously published studies
from Korea or from other countries [19–21, 25–35].
However, similar results were found in a large outpatient
American population, wherein most subjects (80.3 %)
filled prescriptions for a single drug from the previously
published 2003 Beers Criteria [34], and in a study of
Japanese long-term care facilities, wherein 86.5 % of
subjects were treated with at least one medication from
the 2003 Beers Criteria [27].
One reason for such a high prevalence of PIM prescrib-
ing could be the fact that there is no system to inhibit
patients from moving from one physician to another, so
called “doctor-shopping”, which could have allowed a
higher PIM prescription. Moreover, before 2010 when the
drug utilization review was introduced in Korea, physi-
cians could not have recognized overlapping prescriptions.
Among the list of medications or medication classes
considered inappropriate for any patient 65 years of age
and older, the prevalence of benzodiazepines (short,
intermediate, and long acting) was high. The fact that
benzodiazepines were one of the most commonly
prescribed PIM classes was similar to the results of other
studies, although the prevalence itself was much higher
in our study [20, 30, 35]. Meanwhile, among PIM pre-
scriptions for specific diagnoses or conditions, more
than 80 % of subjects diagnosed with delirium, dementia,
and cognitive impairment, all of whom must strongly
avoid benzodiazepines and anticholinergics [36]—were
prescribed at least one PIM.
The high prescription rate of benzodiazepines can be
attributed to the high prevalence of insomnia in older
adults. Notably, this is associated with increased age,
female sex, and the use of benzodiazepines [37–39]. In
Korea, older adults with insomnia can easily get benzo-
diazepine prescriptions from primary care facilities,
which do not need to be specialized in psychiatry.
First-generation antihistamines with anticholinergic
properties and pain medications were the most com-
monly prescribed PIMs in this study (Table 2). Antihista-
mines with anticholinergic properties are often prescribed
as supportive medications for common cold, while pain-
killers are often administered to older adults with musculo-
skeletal pain (which is mainly due to arthritis). First-
generation antihistamines are cheaper than second- or
third-generation antihistamines (approximately 1–4 vs. 18–
22 US cents per tablet), and nonsteroidal anti-inflammatory
drugs (NSAIDs) are cheaper than COX-2 inhibitors (ap-
proximately 9–13 vs. 49–57 cents per tablet) [40]; thus,
physicians may prefer to prescribe cheaper medications, ac-
counting for the high prevalence of anticholinergics and
pain medication prescriptions.
With respect to the risk factors associated with pre-
scription of PIMs independent of disease or condition,
Table 4 Multivariate regression analysis for factors associated with prescription of PIMa according to the 2012 Beers Criteria
Subjects with 1–4 PIM claims Subjects with ≥5 PIM claims
Characteristics OR (95% CI) OR (95% CI)
Age, 65–69 years
70–74 0.98 (0.89–1.09) 1.16 (1.10–1.22)
75–79 1.16 (1.05–1.29) 1.33 (1.26–1.41)
80–84 1.50 (1.34–1.69) 1.61 (1.51–1.72)
≥85 1.89 (1.64–2.18) 1.93 (1.78–2.09)
Female gender 1.19 (1.17–1.21) 1.53 (1.48–1.59)
Specialty other than physician 1.23 (1.22–1.24) 1.46 (1.43–1.50)
Other than primary care facilities 0.84 (0.83–0.85) 0.72 (0.71–0.73)
Rural area 1.02 (1.00–1.04) 0.85 (0.82–0.88)
Insured by NHIb 0.88 (0.85–0.90) 0.83 (0.78–0.88)
No. of OPDc visits within 1 year (≤1 vs. >1) 0.79 (0.78–0.80) 0.68 (0.65–0.71)
Severity of comorbiditiesd 1.21 (1.19–1.22) 2.25 (2.20–2.31)
Polypharmacye 3.51 (3.46–3.56) 7.81 (7.56–8.06)
aPIM, potentially inappropriate medication; bNHI, national health insurance; cOPD, outpatient department; dBased on Charlson Comorbidity Index13; ePolypharmacy
defined as ≥6 medications prescribed in one claim24
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female sex [27, 28, 30], severity of comorbidities based on
the Charlson Comorbidity Index [24], and polypharmacy
[25, 28, 33] were significant risk factors, as has been found
in other studies. In subjects with one to four PIM claims,
residing in a rural area was associated with an increased
risk of PIM prescription, which coincides with the results
of a study published by the US Department of Veterans
Affairs [41]. In contrast, in subjects with ≥5 PIM claims,
living in rural areas seemed to decrease the risk of PIM
prescription. We postulated that older adults who received
five or more PIMs would have greater comorbidities and
the severity of such comorbidities would be higher; as
such, they would require treatment in facilities other than
primary care (i.e., secondary or tertiary care facilities). In
other words, subjects who received five or more PIMs
would probably reside in urban areas, where secondary or
tertiary care facilities are more commonly located. Thus, it
seemed that in this subgroup living in rural areas would
decrease the risk of PIM prescription.
The main strength of the present study was the use of a
large sample size and a national sample of prescription
drug claims, which both allow for generalization of our re-
sults to the entire Korean elderly population. Furthermore,
we determined PIM prevalence using claim records, which
did not depend on subjects’ memory; thus, we were able
to avoid recall and selection biases. To our knowledge,
this is the first study to evaluate PIM prescription rates in
a large outpatient Korean population using the 2012 Beers
Criteria.
Nevertheless, there are also some limitations. First, the
diagnoses in the KHIRA database may not reflect the
actual diagnoses. Therefore, some diseases might be
under-diagnosed leading to a lower PIMs prescription
estimation. On the contrary, some diseases might have
been over-diagnosed causing an overestimation of the
PIMs prevalence. However, one report noted that approxi-
mately 70 % of discharge diagnoses match the medical
records of the hospitals [42]. Second, we analyzed the
database of prescription behaviors, and did not collect
data on drug-taking behaviors; thus, we cannot be sure
that the drugs prescribed in the claims were actually con-
sumed. Third, the 2012 Beers Criteria do not include
drug-to-drug interactions or drugs for which dose adjust-
ment is recommended in chronic kidney patients. Some
PIMs might have not be included in the analysis due to
the lack of this information. Fourth, there may be genetic
differences in some drug-metabolizing enzymes [27],
which could mean that some drugs classified as PIM ac-
cording to the Beers criteria, might not suppose a real
threat to Korean elderly adults. Fifth, there may be drugs
only available in the United States listed in the Beers Cri-
teria and vice-versa — in other words, some drugs that
are only available in Korea and thus are not listed in the
Beers Criteria may be PIMs for Korean elderly adults.
Finally, we lacked detailed clinical information on each
subject, meaning that we cannot ignore the fact that, in
some circumstances, the use of a PIM may be clinically
justifiable if the benefits outweigh the risks to the subject.
Because of the possibility of genetic differences in drug
metabolism and because of the different drug lists avail-
able in each country, other tools, such as McLeod’s Cri-
teria (1997) [4], the Improving Prescribing in the Elderly
Tool (IPET) from Canada (1997) [43], the French con-
sensus panel list (2007) [6], the Screening Tool of Older
Person's Prescriptions/Screening Tool to Alert Doctors
to Right Treatment (STOPP/START) from Ireland
(2008) [7], the Australian prescribing indicators (2008)
[8], the Norwegian general practice criteria (2009) [9],
the Guideline for Appropriate Drug Use in the Elderly in
Korea (2009) [10], and the Korean PIMs list developed
in 2010 using the Delphi method [44] might also be
needed to properly screen PIM prescriptions. In
addition, analyses of drug-to-drug interactions and of
dose adjustment for drugs considering impaired kidney
function in Korean older adults using the most recently
updated 2015 Beers Criteria [45] will be required.
Based on the high prevalence of PIMs prescribing
shown in this study, efforts must be made to improve
and optimize prescribing behavior in clinical practice.
Introducing developed tools and technologies such as
drug utilization review and computerized physician
order entry with decision support [46] could help re-
duce PIMs prescription. Furthermore, more clinical and
laboratory data are needed to strengthen the sensitivity
and specificity of these tools and technologies.
Conclusions
The results of this study showed that there is a very high
prevalence of PIM prescriptions in Korea, which corre-
sponds to the findings of previously published studies.
Notably, the prescription rates of benzodiazepines, anti-
cholinergics, and pain medications were the highest.
Further development of strategies to reduce PIM pre-
scriptions are needed and additional studies, including
reviews of the medical records of subjects with such pre-
scriptions, are also needed to identify the risk factors
fostering the high prescription rates of these drugs. Fi-
nally, studies to confirm the consequences of prescribing
PIMs and the effectiveness of clinical decision support-
ing systems on healthcare outcomes are also essential.
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